About
The Collaborative Research Centre TRR 221 is a network of doctors and scientists working together to improve treatments for patients with blood cancers like leukemia. Our focus is on a type of treatment called allogeneic stem cell transplantation, where a patient receives healthy blood stem cells from a donor. While this treatment can save lives, it also brings important risks. The donor’s immune cells can attack any remaining cancer cells — a powerful effect known as graft-versus-leukemia (GvL). However, these same cells can also attack the patient’s healthy tissues, leading to a potentially serious complication called graft-versus-host disease (GvHD).
Our goal is to better understand how the immune system behaves after transplantation, so we can keep the parts that fight cancer and reduce the parts that cause harm.
CRC TRR 221 is funded by the German Research Foundation (DFG) and involves top medical and research institutions:
University of Regensburg
Friedrich-Alexander-Universität Erlangen-Nürnberg
University of Würzburg, University Hosp
Together, our researchers are developing new therapies, including immunotherapies and cell-based treatments, that aim to make stem cell transplants safer and more effective for patients.
By combining the latest science with real-world medical care, CRC TRR221 is helping to shape the future of cancer treatment — and giving patients a better chance at long-term recovery.
